SlideShare a Scribd company logo
1 of 12
Dr. Peter Ungeheuer
Secretary General
Mainzer Landstrasse 55
D - 60329 Frankfurt
EFfCI Head Office: Avenue Louise 489, B-1050 Brussels 
Phone: +49-69-25 5613 41
E-mail: Ungeheuer@effci.com
Fax: +49-69-25 56 1342
HTTP://WWW.EFFCI.COM
EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059
EFfCI GMP for Cosmetic Ingredients – Annex to 2017 Edition
Cosmetic Ingredientmanufacturer anddistributor certification;
Application of remote audits
Frankfurt, January 14th
, 2021
Purpose and Objectives:
Conducting an EFfCI GMP audit may be impossible in the very exceptional situation where
countries are in lockdown as a result of the COVID-19 pandemic crisis. The safety of people
that conduct and receive audits is top priority for EFfCI and we support those governmental
regulations which are aimed at reducing the impact of this virus. Even if travel was possible
then company policies may mean many personnel are working from home and operational
activities reduced or even halted. All these factors will have consequences with regards to
EFfCI GMP Audits.
The goal of this document is to describe alternative options where a physical audit is not
permitted, to maintain or to renew the GMP Certification of Cosmetic Ingredient manufacturers
and distributors. It indicates the conditions and time-periods which are acceptable to postpone
a re-certification or surveillance audit or to replace it by a remote audit.
It will be communicated to each EFfCI Registered Certification Body for implementation in their
internal procedures.
Supporting documents:
- EFfCI GMP for Cosmetic Ingredients 2017
- EFfCI Position Paper: Cosmetic Ingredient manufacturer and distributor certification
with regards to the COVID-19 outbreak (13 March 2020)
- IAF ID3 2011 Guidance: International Accreditation Forum (IAF) Informative Document
for Management of Extraordinary Events or Circumstances Affecting Accreditation
Bodies, Certifying [Assessment] Bodies and Certified Organisations
https://www.iaf.nu/articles/Informative_Documents_/32
1. Scope
This document should be followed by EFfCI Registered Certification Bodies, when a
scheduled audit is affected by an extraordinary circumstance such as a government-
imposed travel ban, or other restrictions applied externally to the Cosmetic Ingredient
manufacturer and/or supplier which are beyond their control.
The annex applies to EFfCI GMP re-certification or surveillance audits and the first part of
an initial Certification audit (Stage-1) audit. However, the full on-site initial Certification
audit (Stage 2 audit) has to completed with a physical on-site audit.
These requirements are valid while the COVID-19 pandemic containment measures are in
place in the affected countries. It should remain valid until local or national travel
restrictions are suspended, and physical (on-site) audits can return to normal.
Dr. Peter Ungeheuer
Secretary General
Mainzer Landstrasse 55
D - 60329 Frankfurt
EFfCI Head Office: Avenue Louise 489, B-1050 Brussels 
Phone: +49-69-25 5613 41
E-mail: Ungeheuer@effci.com
Fax: +49-69-25 56 1342
HTTP://WWW.EFFCI.COM
EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059
2. Definitions
Extraordinary event or circumstance: A circumstance beyond the control of the certified
company, commonly referred to as “Force Majeure” or “act of God”. Examples are
war, strike, riot, political instability, geopolitical tension, terrorism, crime, pandemic, flooding,
earthquake, malicious computer hacking, other natural or man-made disasters.
3. Responsibilities
It is the responsibility of the Certification Body to implement these requirements in its own
system of procedures for communication to its team of auditors. The Certification Body
shall also communicate these requirements to their impacted Cosmetic Ingredient Suppliers
in case a certification audit cannot be performed for the above reason.
It is the responsibility of the Certification Body to inform EFfCI aisbl (ungeheuer@effci.com)
about the decision to either postpone or to perform a remote certification audit, before the
audit is completed.
4. Procedure: conditions for postponement or remote audit
4.1. Initial Certification Audit
When a new supplier of a Cosmetic Ingredient is willing to be certified with reference to the
EFfCI GMP, the Stage 1 audit may be performed remotely. However, a Stage 2 audit
cannot be conducted remotely. The Stage 2 certification audit shall be made no later than 6
months after the Stage 1 audit. If such conditions cannot be fulfilled, the best solution would
be to wait until an on-site Stage 1 and Stage 2 certification audit can be completed.
It is the decision of the Lead Auditor and of the Certification Body to accept a Stage 1
remote audit instead of on-site audit. Such a decision should consider the previous
knowledge of the client, the scope of the certification, the size of the site, the number of
products to be included in the assessment and the complexity of the production processes.
The Lead Auditor should also take into consideration the probability for performing a Stage
2 on-site audit within a 6 months’ time period, before performing a remote Stage 1 audit.
It is acknowledged that it may not be possible to perform a physical audit for Stage 2, and
this may mean the application has to lapse. At this point EFfCI does not believe that this
physical audit can be omitted without seriously compromising the reputation and value of
the Certification Scheme to cosmetic manufacturers.
4.2. SurveillanceAudit
a) When a Surveillance Audit 1 (SA-1) cannot be performed within one year after the Initial
Certification Audit, or when a Surveillance Audit 2 (SA-2) cannot be performed within
two years after the Initial Certification Audit, the physical audit can be delayed for a
maximum of 6 months after the initial scheduled date. The initial scheduled date must
be considered as the last day of the initial certification audit plus 12 or 24 months.
Therefore, SA-1 should be conducted maximum 18 months after the initial certification
audit and SA-2 should be conducted maximum 30 months after the initial certification
audit date.
The normal window which is applied to all scheduled audits should be respected based
on the revised date.
Dr. Peter Ungeheuer
Secretary General
Mainzer Landstrasse 55
D - 60329 Frankfurt
EFfCI Head Office: Avenue Louise 489, B-1050 Brussels 
Phone: +49-69-25 5613 41
E-mail: Ungeheuer@effci.com
Fax: +49-69-25 56 1342
HTTP://WWW.EFFCI.COM
EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059
b) If such an on-site audit is not possible for the reasons in the purpose and objectives, it
may be acceptable to perform a remote audit in place of physical audit. This should be
completed within the 6 month period after the initially scheduled audit date.
The Certification Body shall as a first step perform a quality risk assessment considering
the conditions mentioned in section 5.2 “Quality Risk Assessment for allowing a remote
audit”. If the conclusion is that risk is low or moderate, the Certification Body can
propose to the Supplier that a remote audit according to the procedure described in
Section 5 can be conducted. The remote audit will then replace the on-site audit. If the
SA-1 was already performed using remote means, then the SA-2 can also be a remote
audit if the risk assessment is reviewed, revised and has a favorable conclusion (it is
now permitted that there can be two successive remote surveillance audits).
c) If the quality risk assessment concludes a remote audit is not acceptable, or if for any
other reason a remote audit cannot be performed, then the EFfCI Certification shall be
suspended for a maximum 6 months period and be withdrawn immediately after 6
months.
d) In any case, the Certification Body should inform EFfCI aisbl at ungeheuer@effci.com
about the audit’s postponement or the completion of a remote audit or a certification
suspension, before the decision is implemented.
4.3. Re-certification Audit
One of the following three options may be adopted:
a) If a re-certification audit (RCA) cannot be performed within the normal window following
the third anniversary of the Initial Certification Audit, the audit can be delayed for a
maximum of 6 months after the third anniversary date.
Therefore, an RCA should be conducted no later than 42 months after the initial
certification audit date. In this case, there should be an extension of the expiry date of
the certificate.
b) If an on-site audit is not possible for the reasons in the purpose and objectives, it may
be acceptable to perform a remote audit, in accordance with Section 5, in order to
replace an on-site physical audit and to avoid certification suspension. That is the
recertification audit in its entirety can be replaced by a remote audit.
The Certification Body shall initially perform a quality risk assessment considering the
conditions mentioned in Section 5.2 “Quality Risk Assessment for allowing a remote
audit”. If the conclusion is that risk is low or moderate, the Certification Body can
propose a remote audit according to the procedure described in Section 5.
If the quality risk assessment is favorable, the remote audit shall be conducted within 6
months of the original planned RCA date, i.e., not more than 42 months after the initial
certification audit (to allow time for planning and organizing the remote audit). In such an
option, the remote audit shall also be confirmed by an on-site audit within the 6 month
period after the date of the remote audit. In this case, there should be an extension of
the expiry date of the certificate to the date of the remote audit. This means the physical
audit will fall within the next audit cycle for the Certificate, but it should be an exceptional
one off circumstance. This on-site audit duration can be shorter as the documentation
was already assessed during the remote audit.
c) If the quality risk assessment concludes a remote audit is not acceptable, or if no
physical audit is possible within the 6 month extension in section a) then the EFfCI
Dr. Peter Ungeheuer
Secretary General
Mainzer Landstrasse 55
D - 60329 Frankfurt
EFfCI Head Office: Avenue Louise 489, B-1050 Brussels 
Phone: +49-69-25 5613 41
E-mail: Ungeheuer@effci.com
Fax: +49-69-25 56 1342
HTTP://WWW.EFFCI.COM
EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059
Certification shall be suspended for a maximum 6 months period from the date of the
original scheduled RCA and withdrawn immediately after.
Dr. Peter Ungeheuer
Secretary General
Mainzer Landstrasse 55
D - 60329 Frankfurt
EFfCI Head Office: Avenue Louise 489, B-1050 Brussels 
Phone: +49-69-25 5613 41
E-mail: Ungeheuer@effci.com
Fax: +49-69-25 56 1342
HTTP://WWW.EFFCI.COM
EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059
d) In all cases, the Certification Body should inform EFfCI at ungeheuer@effci.com about
the audit’s postponement, application of a remote audit or certification suspension,
before the decision is implemented in order for this to be updated on the EFfCI website.
4.4. Certification Scope Changes
Where an organization requires an additional location to be added to the scope of
certification, then a physical audit of that location is required. If this cannot be completed
then no change to the certification scope can be completed.
4.5. Certificate Validity
The recertification date on Certificates will be retained as originally established. This means
that if an audit is delayed under these rules and a new one issued the validity period of the
new certificate will be the third year of the anniversary of the end of the validity of the
previous certificate. That is, any delay to the audit will not increase the period of validity of
the certificate.
5. Procedure: Organization ofa Remote audit
A remote audit is an audit which is performed under a confidential disclosure agreement by
remote tools (e.g.: phone, e-mails, Skype, WhatsApp, Zoom), with exchange of electronic
documents using internet-cloud system when the size of document cannot be transferred by
direct mails (e.g.: WeTransfer, Dropbox). The auditor may also be granted temporary
access to the client’s IT systems to observe information directly.
A remote audit is different from a questionnaire assessment as there should be a direct
discussion between the auditor and the auditee, and the use of a video-conferencing
system is essential.
A remote audit is also different from a simple teleconference as the auditor shall have the
opportunity to read and assess written audit evidence which is displayed on screen.
At the end of the remote audit, it should be considered that, as far as audited topics are
concerned, the Lead Auditor shall be able to provide a recommendation about the audit
outcome with the same degree of confidence as after a physical audit. A remote audit does
not have to include an on-site visit and audit of workshops, laboratories and warehouses
but any visual evidence of these locations that can be provided is to be considered.
5.1. Confidentiality agreement
The realisation of a remote audit will require some exchange of documents and
photographs prior to the audit. Therefore, the existing confidentiality agreement may need
to be revised and strengthened. The method of information exchange should be agreed in
advance including the storage, processing, retaining and disposal of the shared information.
There should be a prior commitment to keep confidential any information shared before and
during the audit, and to not to copy or archive any photograph or document unless formally
agreed by the auditee.
5.2. Quality Risk Assessment for allowing a remote audit
A quality risk assessment should be performed by the Certification Body, with input from the
client, before deciding if a remote audit can be conducted. EFfCI should be consulted if
there is any doubt about the risk assessment outcome. The conclusion of the risk
Dr. Peter Ungeheuer
Secretary General
Mainzer Landstrasse 55
D - 60329 Frankfurt
EFfCI Head Office: Avenue Louise 489, B-1050 Brussels 
Phone: +49-69-25 5613 41
E-mail: Ungeheuer@effci.com
Fax: +49-69-25 56 1342
HTTP://WWW.EFFCI.COM
EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059
assessment should be based on knowledge of the client, any publicly available information
about their quality systems, and preliminary information provided by the client.
Dr. Peter Ungeheuer
Secretary General
Mainzer Landstrasse 55
D - 60329 Frankfurt
EFfCI Head Office: Avenue Louise 489, B-1050 Brussels 
Phone: +49-69-25 5613 41
E-mail: Ungeheuer@effci.com
Fax: +49-69-25 56 1342
HTTP://WWW.EFFCI.COM
EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059
The risk assessment for determining whether to permit a remote audit, shall be
documented. The risk assessment and the fact the audit was conducted remotely shall be
clearly and prominently stated in the audit report.
The risk assessment shall at a minimum consider the following items:
- Changes to the certification scope (automatic high risk factor)
- Changes to the production site address or major changes to the production facilities
(e.g. new plant installed, new manufacturing process) (automatic high risk factor)
- Changes to the types of Products manufactured in the same plant or using the same
production equipment (automatic high risk factor)
- Quality Complaint(s) communicated the Certification Body, concerning a Supplier
Quality System deficiency (automatic high risk factor)
- The number of major non-conformities at any or each of the previous two audits (more
than three would be a high risk factor)
- The history of closure of actions on the previous three audits
- The numbers of all other observations (all types) in the previous three audits
- Changes to the quality and or site management team since the last audit
5.3. Preparation and duration ofa remote audit
The success of a remote audit will depend on the possibility for both the auditor and the
auditee to have direct exchange concerning the quality matters that are not limited to a
review of documentation only. The use of videoconference instead of a voice-only
teleconference may facilitate such exchanges. It is also very important that auditor has a
direct view of a requested document and the opportunity to ask questions and to receive
immediate answers during the review.
The time for connection with the attendees should be carefully managed, as well as the
access to documents in the interviews.
During the audit preparation phase the communication tools to be used shall be agreed. It is
recommended these be tested, including the ability to exchange documents a few days
before the audit.
A list of documents which the auditor needs to see shall be communicated in advance, with
the audit schedule. Additional documented evidence may be requested during the audit.
In case translation is needed between the auditor and the auditee, the parties should agree
prior to the audit how this will be managed.
The total audit duration should be not less than the one defined for the original on-site
physical audit. For instance, if a surveillance audit is defined to last one day, the remote
surveillance audit should last not less than 8 hours. It is recommended to organise the
remote audit agenda into several sections. This will allow named auditee’ employees to be
present to discuss relevant concerns, and the auditor to have time to assess documents on
their own. The remote audit may be organised over several days, with only a few hours per
day for the interview.
An example agenda corresponding to remote audit organisation is proposed in the
Appendix.
5.4. Realisation of a remote audit
The remote audit shall follow the same basic steps as a physical audit:
- Audit program (the audit program should mention that it is a remote audit)
Dr. Peter Ungeheuer
Secretary General
Mainzer Landstrasse 55
D - 60329 Frankfurt
EFfCI Head Office: Avenue Louise 489, B-1050 Brussels 
Phone: +49-69-25 5613 41
E-mail: Ungeheuer@effci.com
Fax: +49-69-25 56 1342
HTTP://WWW.EFFCI.COM
EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059
- Receipt of documents prior to the interview and study of them
Dr. Peter Ungeheuer
Secretary General
Mainzer Landstrasse 55
D - 60329 Frankfurt
EFfCI Head Office: Avenue Louise 489, B-1050 Brussels 
Phone: +49-69-25 5613 41
E-mail: Ungeheuer@effci.com
Fax: +49-69-25 56 1342
HTTP://WWW.EFFCI.COM
EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059
- Opening meeting
- Interview of Cosmetic Ingredient supplier teams
- Assembly of objective evidence
- Closing meeting
- Audit Report issuance (The audit report should mention it is a remote audit which
was justified based on a documented risk assessment.)
- Supplier’s commitment for improvement – CAPA plan assessment
- Final auditor recommendation regarding EFfCI GMP Certification status
- Certification Body Certification decision
- Communication of the certification conclusion
If there is no remote visual visit to the plant (for example because of safety concerns such
as explosive zoning), the auditor may request specific photographs of e.g., the production
area and utilities. The auditor may also request raw data using a shared screen in case of
electronic data or using webcam pictures of paper documentation.
The organisation of such a remote audit should ensure when auditee representatives for
each topic and each function are available in a timely manner.
5.5. Contentof the remote audit: Items to be audited
The remote audit shall consider the key items listed in the EFfCI GMP Standard for
Cosmetic Ingredients (non- exhaustive list):
a) CAPA from the previous audit:
Any previous preventive and corrective action plan should be reviewed, and evidence
obtained (e.g. pictures and/or documents) to demonstrate action closure. This evidence
may be requested during the audit preparation phase.
b) List of Changes implemented since the previous audit:
New equipment, new products, change of process, new activity within the site, change
of organisation.
For each change, an impact assessment should be available. Such change should be
considered as of minor importance with regards to quality of manufactured Cosmetic
Ingredient, otherwise a remote audit cannot replace an on-site audit.
c) Annual Management Review:
Performance of manufacturing operations and the quality system (e.g. Number of
batches manufactured, number of batches rejected, customer complaints, recalls)
Customer satisfaction assessment.
Quality and GMP Objectives and Targets and the results of any previous ones
d) Batch Record:
At least one production and quality control batch record should be assessed by the
auditor. The auditor should be able to select the batch record to be audited.
A specific focus should be made on the testing, release and shipment process.
e) Quality Control:
Organisation of the QC, role and responsibilities.
Audit of an actual analytical batch record with specific focus on raw data traceability
Number of out-of-specification results recorded since previous audit.
Issuance of Certificate of Analysis or Certificate of Conformity.
f) Certification and Inspections
Dr. Peter Ungeheuer
Secretary General
Mainzer Landstrasse 55
D - 60329 Frankfurt
EFfCI Head Office: Avenue Louise 489, B-1050 Brussels 
Phone: +49-69-25 5613 41
E-mail: Ungeheuer@effci.com
Fax: +49-69-25 56 1342
HTTP://WWW.EFFCI.COM
EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059
ISO 9001 audits and outcomes if those audits are performed separately to the EFfCI
GMP audit.
Dr. Peter Ungeheuer
Secretary General
Mainzer Landstrasse 55
D - 60329 Frankfurt
EFfCI Head Office: Avenue Louise 489, B-1050 Brussels 
Phone: +49-69-25 5613 41
E-mail: Ungeheuer@effci.com
Fax: +49-69-25 56 1342
HTTP://WWW.EFFCI.COM
EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059
g) Internal Audits
Annual program, list and duration of the audits performed, process review
Processes covered by the internal audit program since previous audit.
h) Suppliers’ and Contractors’ Management
New suppliers, monitoring of approved suppliers, audit of contractors, qualification
evidence.
i) Organisation roles and Responsibilities
Number of employees (changes since previous audit), percentage of temporary
employees.
Organisation chart and corresponding job descriptions.
j) Personnel Qualification
GMP training program and realization
Reference to EFfCI standards
Example of training program traceability
Management of consultants and temporary employees, if any
k) Infrastructure and Working Environment Risk Assessments
Changes to these documents resulting in new controls being applied to utilities,
infrastructure and the working environment.
6. DocumentHistory
1 17th
April 2020 First Issue
2 6th
October 2020 Second edition with updates (in red text)
3 14th
January 2021 Addition of Section 4.4 and 4.5 and editorial corrections
Dr. Peter Ungeheuer
Secretary General
Mainzer Landstrasse 55
D - 60329 Frankfurt
EFfCI Head Office: Avenue Louise 489, B-1050 Brussels 
Phone: +49-69-25 5613 41
E-mail: Ungeheuer@effci.com
Fax: +49-69-25 56 1342
HTTP://WWW.EFFCI.COM
EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059
7. APPENDIX: Example ofRemote Audit Agenda
Day Time Participant Topic to be audited Technical tool
D-1
08:30 All Opening Meeting – roundtable, test of
connection, scope – objectives
Videoconference
09:15 concerned
managers
Discussion of CAPA from previous
audit (based on document provided
prior the audit)
Videoconference
10:00 Break
10:15 Team 1
(e.g.: HR +
QA)
Topic 1
(e.g.: Training & personal qualification)
webcam &
shared screen
10:45 Team 2 Topic 2 webcam &
shared screen
11:10 Team 3 Topic 3 webcam &
shared screen
11:30 Auditee Team
Leader
Request for additional documentation e-Mail, Cloud
transfer
11:45 Break
12:00
12:30
Auditee’s
team
Preliminary feedback after Day 1,
documents to be prepared for Day 2
Videoconference
D-1
Afternoon
Auditor only Review documentation, request for
additional evidence, communication to
the auditee’s team leader
Mail, phone,
office work
D-2
08:30 Auditee’s
team
Day-2 introduction meeting
Program of the 2nd
day
Availability of Company representatives
webcam &
shared screen
09:00 Team 4 Topic 4 webcam &
shared screen
09:20 Team 5 Topic 5 webcam &
shared screen
09:40 Team 6 Topic 6 webcam &
shared screen
10:00 Auditee’s
team
Auditor ask for documents,
photographs, other evidence
webcam &
shared screen
10:05 Break
10:20 Ad-hoc team Last item(s) to be audited,
last questions about provided
documentation
webcam &
shared screen
11:15
Auditor time
Room / Tool
change
11:45 All Audit Conclusion meeting
List of non-conformities and
observations
Videoconference
12:30 End of the audit

More Related Content

What's hot

What's hot (20)

Malaysia Medical Devices Regulations
Malaysia Medical Devices RegulationsMalaysia Medical Devices Regulations
Malaysia Medical Devices Regulations
 
Pharmaceutical Licecnsing authorites of india
Pharmaceutical Licecnsing authorites of indiaPharmaceutical Licecnsing authorites of india
Pharmaceutical Licecnsing authorites of india
 
Gayatree dra
Gayatree draGayatree dra
Gayatree dra
 
Who prequalification program
Who prequalification programWho prequalification program
Who prequalification program
 
Device registration ppt
Device registration pptDevice registration ppt
Device registration ppt
 
CENTRAL DRUG STANDARD CONTROL ORGANISATION (CDSCO)
CENTRAL DRUG STANDARD CONTROL ORGANISATION  (CDSCO)CENTRAL DRUG STANDARD CONTROL ORGANISATION  (CDSCO)
CENTRAL DRUG STANDARD CONTROL ORGANISATION (CDSCO)
 
Medical Device Administration In China
Medical Device Administration In ChinaMedical Device Administration In China
Medical Device Administration In China
 
Certification
CertificationCertification
Certification
 
Medical Devices Rules 2017 Implementation
Medical Devices Rules 2017 ImplementationMedical Devices Rules 2017 Implementation
Medical Devices Rules 2017 Implementation
 
Clinical trial regulation 2019
Clinical trial regulation 2019Clinical trial regulation 2019
Clinical trial regulation 2019
 
Mdr 17 with 2020 rules
Mdr 17 with 2020 rulesMdr 17 with 2020 rules
Mdr 17 with 2020 rules
 
New ct rule 2019
New ct rule 2019New ct rule 2019
New ct rule 2019
 
Cdsco
CdscoCdsco
Cdsco
 
Pakistan Medical Device regulatory process
Pakistan Medical Device regulatory processPakistan Medical Device regulatory process
Pakistan Medical Device regulatory process
 
Tabular summary of New Drugs & Clinical Trials Rules, 2019 [INDIA]
Tabular summary of New Drugs & Clinical Trials Rules, 2019 [INDIA]Tabular summary of New Drugs & Clinical Trials Rules, 2019 [INDIA]
Tabular summary of New Drugs & Clinical Trials Rules, 2019 [INDIA]
 
Central Drugs Standard Control Organization (CDSCO)
Central Drugs Standard Control Organization (CDSCO)Central Drugs Standard Control Organization (CDSCO)
Central Drugs Standard Control Organization (CDSCO)
 
CDSCO and ADR reporting in India
CDSCO and ADR reporting in IndiaCDSCO and ADR reporting in India
CDSCO and ADR reporting in India
 
Bodies regulating indian pharmaceutical sector, cdsco
Bodies regulating indian pharmaceutical sector, cdscoBodies regulating indian pharmaceutical sector, cdsco
Bodies regulating indian pharmaceutical sector, cdsco
 
IVDR Readiness Checklist
IVDR Readiness ChecklistIVDR Readiness Checklist
IVDR Readiness Checklist
 
Licensing of blood bank
Licensing of blood bankLicensing of blood bank
Licensing of blood bank
 

Similar to Chứng nhận nhà sản xuất và phân phối nguyên liệu mỹ phẩm theo EFfCI

BRCGS for Food Safety - issue 9 (Draft).pdf
BRCGS for Food Safety - issue 9 (Draft).pdfBRCGS for Food Safety - issue 9 (Draft).pdf
BRCGS for Food Safety - issue 9 (Draft).pdf
hodahassan26
 
Gc3 guidance and information for accredited course providers and candida..
Gc3 guidance and information for accredited course providers and candida.. Gc3 guidance and information for accredited course providers and candida..
Gc3 guidance and information for accredited course providers and candida..
kamyjoe214
 
Iatf rules 4th clients requirements 2014 01 28 final
Iatf rules 4th clients requirements 2014 01 28 finalIatf rules 4th clients requirements 2014 01 28 final
Iatf rules 4th clients requirements 2014 01 28 final
jacques POULENARD
 

Similar to Chứng nhận nhà sản xuất và phân phối nguyên liệu mỹ phẩm theo EFfCI (20)

Brc unannounced audits bb
Brc unannounced audits bbBrc unannounced audits bb
Brc unannounced audits bb
 
FDA Clarifies The Types Of MDSAP Audits To Be Conducted In The Pandemic
FDA Clarifies The Types Of MDSAP Audits To Be Conducted In The PandemicFDA Clarifies The Types Of MDSAP Audits To Be Conducted In The Pandemic
FDA Clarifies The Types Of MDSAP Audits To Be Conducted In The Pandemic
 
Certificate of pharmaceutical product
Certificate of pharmaceutical productCertificate of pharmaceutical product
Certificate of pharmaceutical product
 
COPP.pptx
COPP.pptxCOPP.pptx
COPP.pptx
 
REGULATORY REQUIREMENTS FOR REGISTRATION OF DRUGS AND POST APPROVAL REQUIREME...
REGULATORY REQUIREMENTS FOR REGISTRATION OF DRUGS AND POST APPROVAL REQUIREME...REGULATORY REQUIREMENTS FOR REGISTRATION OF DRUGS AND POST APPROVAL REQUIREME...
REGULATORY REQUIREMENTS FOR REGISTRATION OF DRUGS AND POST APPROVAL REQUIREME...
 
Pao dti
Pao dtiPao dti
Pao dti
 
PET - Quality Assurance of PET Radiopharmaceutials
PET - Quality Assurance of PET RadiopharmaceutialsPET - Quality Assurance of PET Radiopharmaceutials
PET - Quality Assurance of PET Radiopharmaceutials
 
The eu-clinical-trials-regulation-main-changes-and-challenges
The eu-clinical-trials-regulation-main-changes-and-challengesThe eu-clinical-trials-regulation-main-changes-and-challenges
The eu-clinical-trials-regulation-main-changes-and-challenges
 
BRCGS for Food Safety - issue 9 (Draft).pdf
BRCGS for Food Safety - issue 9 (Draft).pdfBRCGS for Food Safety - issue 9 (Draft).pdf
BRCGS for Food Safety - issue 9 (Draft).pdf
 
FSMA Fridays: GFSI Remote & Virtual Auditing Update
FSMA Fridays: GFSI Remote & Virtual Auditing UpdateFSMA Fridays: GFSI Remote & Virtual Auditing Update
FSMA Fridays: GFSI Remote & Virtual Auditing Update
 
Europe CE Marking for medical devices under new MDR
Europe CE Marking for medical devices under new MDREurope CE Marking for medical devices under new MDR
Europe CE Marking for medical devices under new MDR
 
Overview on audit; A&RC
Overview on audit; A&RCOverview on audit; A&RC
Overview on audit; A&RC
 
Gc3 guidance and information for accredited course providers and candida..
Gc3 guidance and information for accredited course providers and candida.. Gc3 guidance and information for accredited course providers and candida..
Gc3 guidance and information for accredited course providers and candida..
 
Iatf rules 4th clients requirements 2014 01 28 final
Iatf rules 4th clients requirements 2014 01 28 finalIatf rules 4th clients requirements 2014 01 28 final
Iatf rules 4th clients requirements 2014 01 28 final
 
Audits by suhail
Audits by suhailAudits by suhail
Audits by suhail
 
Circular 18/2019/TT-BYT: GUIDELINES ON GOOD MANUFACTURING PRACTICES (GMP) FOR...
Circular 18/2019/TT-BYT: GUIDELINES ON GOOD MANUFACTURING PRACTICES (GMP) FOR...Circular 18/2019/TT-BYT: GUIDELINES ON GOOD MANUFACTURING PRACTICES (GMP) FOR...
Circular 18/2019/TT-BYT: GUIDELINES ON GOOD MANUFACTURING PRACTICES (GMP) FOR...
 
China medical device approval chart - EMERGO
China medical device approval chart - EMERGOChina medical device approval chart - EMERGO
China medical device approval chart - EMERGO
 
Rules and Guidance for Pharmaceutical Manufacturers Distributors 2015 - The G...
Rules and Guidance for Pharmaceutical Manufacturers Distributors 2015 - The G...Rules and Guidance for Pharmaceutical Manufacturers Distributors 2015 - The G...
Rules and Guidance for Pharmaceutical Manufacturers Distributors 2015 - The G...
 
Post-Market Clinical Follow Up Studies Under EU MDR and IVDR
Post-Market Clinical Follow Up Studies Under EU MDR and IVDRPost-Market Clinical Follow Up Studies Under EU MDR and IVDR
Post-Market Clinical Follow Up Studies Under EU MDR and IVDR
 
poct-introduction-training-final-version-for-southern-docs-(2).ppt
poct-introduction-training-final-version-for-southern-docs-(2).pptpoct-introduction-training-final-version-for-southern-docs-(2).ppt
poct-introduction-training-final-version-for-southern-docs-(2).ppt
 

More from Công ty Cổ phần Tư vấn Thiết kế GMP EU

FDA: Practices to Prevent Unsafe Contamunation of Animal Feed from Drug Carvover
FDA: Practices to Prevent Unsafe Contamunation of Animal Feed from Drug CarvoverFDA: Practices to Prevent Unsafe Contamunation of Animal Feed from Drug Carvover
FDA: Practices to Prevent Unsafe Contamunation of Animal Feed from Drug Carvover
Công ty Cổ phần Tư vấn Thiết kế GMP EU
 

More from Công ty Cổ phần Tư vấn Thiết kế GMP EU (20)

Quyết định 878/QĐ-QLD 2023 công bố Danh mục thuốc biệt dược gốc Đợt 5
Quyết định 878/QĐ-QLD 2023 công bố Danh mục thuốc biệt dược gốc Đợt 5Quyết định 878/QĐ-QLD 2023 công bố Danh mục thuốc biệt dược gốc Đợt 5
Quyết định 878/QĐ-QLD 2023 công bố Danh mục thuốc biệt dược gốc Đợt 5
 
DANH MỤC DỰ ÁN GMP - ISO.pptx
DANH MỤC DỰ ÁN GMP - ISO.pptxDANH MỤC DỰ ÁN GMP - ISO.pptx
DANH MỤC DỰ ÁN GMP - ISO.pptx
 
ICH Q11 Combine.pdf
ICH Q11 Combine.pdfICH Q11 Combine.pdf
ICH Q11 Combine.pdf
 
Thực hành tốt bảo quản nguyên liệu làm thuốc (GSP) - Phần II.pptx
Thực hành tốt bảo quản nguyên liệu làm thuốc (GSP) - Phần II.pptxThực hành tốt bảo quản nguyên liệu làm thuốc (GSP) - Phần II.pptx
Thực hành tốt bảo quản nguyên liệu làm thuốc (GSP) - Phần II.pptx
 
Thực hành tốt bảo quản nguyên liệu làm thuốc (GSP) - Phần I.pptx
Thực hành tốt bảo quản nguyên liệu làm thuốc (GSP) - Phần I.pptxThực hành tốt bảo quản nguyên liệu làm thuốc (GSP) - Phần I.pptx
Thực hành tốt bảo quản nguyên liệu làm thuốc (GSP) - Phần I.pptx
 
GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART I.pdf
GUIDE TO GOOD MANUFACTURING PRACTICE  FOR MEDICINAL PRODUCTS PART I.pdfGUIDE TO GOOD MANUFACTURING PRACTICE  FOR MEDICINAL PRODUCTS PART I.pdf
GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS PART I.pdf
 
Danh sách các cơ sở trong nước đạt tiêu chuẩn nguyên tắc GLP. pdf
Danh sách các cơ sở trong nước đạt tiêu chuẩn nguyên tắc GLP. pdfDanh sách các cơ sở trong nước đạt tiêu chuẩn nguyên tắc GLP. pdf
Danh sách các cơ sở trong nước đạt tiêu chuẩn nguyên tắc GLP. pdf
 
ISPE Good manufacturing practice
ISPE Good manufacturing practiceISPE Good manufacturing practice
ISPE Good manufacturing practice
 
Hồ sơ năng lực GMP EU
Hồ sơ năng lực GMP EUHồ sơ năng lực GMP EU
Hồ sơ năng lực GMP EU
 
Prequalified Active Pharmaceutical Ingredients.pptx
Prequalified Active Pharmaceutical Ingredients.pptxPrequalified Active Pharmaceutical Ingredients.pptx
Prequalified Active Pharmaceutical Ingredients.pptx
 
Danh mục 37 thuốc sản xuất trong nước được cấp giấy phép lưu hành tại Việt Na...
Danh mục 37 thuốc sản xuất trong nước được cấp giấy phép lưu hành tại Việt Na...Danh mục 37 thuốc sản xuất trong nước được cấp giấy phép lưu hành tại Việt Na...
Danh mục 37 thuốc sản xuất trong nước được cấp giấy phép lưu hành tại Việt Na...
 
Danh mục 259 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việ...
Danh mục 259 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việ...Danh mục 259 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việ...
Danh mục 259 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việ...
 
QUYẾT ĐỊNH 438/QĐ-QLD VỀ VIỆC CÔNG BỐ DANH MỤC THUỐC BIỆT DƯỢC GỐC - ĐỢT 2 NĂ...
QUYẾT ĐỊNH 438/QĐ-QLD VỀ VIỆC CÔNG BỐ DANH MỤC THUỐC BIỆT DƯỢC GỐC - ĐỢT 2 NĂ...QUYẾT ĐỊNH 438/QĐ-QLD VỀ VIỆC CÔNG BỐ DANH MỤC THUỐC BIỆT DƯỢC GỐC - ĐỢT 2 NĂ...
QUYẾT ĐỊNH 438/QĐ-QLD VỀ VIỆC CÔNG BỐ DANH MỤC THUỐC BIỆT DƯỢC GỐC - ĐỢT 2 NĂ...
 
FDA: Practices to Prevent Unsafe Contamunation of Animal Feed from Drug Carvover
FDA: Practices to Prevent Unsafe Contamunation of Animal Feed from Drug CarvoverFDA: Practices to Prevent Unsafe Contamunation of Animal Feed from Drug Carvover
FDA: Practices to Prevent Unsafe Contamunation of Animal Feed from Drug Carvover
 
FDA: Guidance-Labeling Infant Formula-March2023
FDA: Guidance-Labeling Infant Formula-March2023FDA: Guidance-Labeling Infant Formula-March2023
FDA: Guidance-Labeling Infant Formula-March2023
 
QUYẾT ĐỊNH 353/QĐ-QLD: Ban hành danh mục 69 thuốc sản xuất trong nước được cấ...
QUYẾT ĐỊNH 353/QĐ-QLD: Ban hành danh mục 69 thuốc sản xuất trong nước được cấ...QUYẾT ĐỊNH 353/QĐ-QLD: Ban hành danh mục 69 thuốc sản xuất trong nước được cấ...
QUYẾT ĐỊNH 353/QĐ-QLD: Ban hành danh mục 69 thuốc sản xuất trong nước được cấ...
 
QUYẾT ĐỊNH SỐ 352/QĐ-QLD VỀ VIỆC BAN HÀNH DANH MỤC 231 THUỐC SẢN XUẤT TRONG N...
QUYẾT ĐỊNH SỐ 352/QĐ-QLD VỀ VIỆC BAN HÀNH DANH MỤC 231 THUỐC SẢN XUẤT TRONG N...QUYẾT ĐỊNH SỐ 352/QĐ-QLD VỀ VIỆC BAN HÀNH DANH MỤC 231 THUỐC SẢN XUẤT TRONG N...
QUYẾT ĐỊNH SỐ 352/QĐ-QLD VỀ VIỆC BAN HÀNH DANH MỤC 231 THUỐC SẢN XUẤT TRONG N...
 
QUYẾT ĐỊNH 371/QĐ-QLD VỀ VIỆC CÔNG BỐ DANH MỤC THUỐC BIỆT DƯỢC GỐC ĐỢT 1 - NĂ...
QUYẾT ĐỊNH 371/QĐ-QLD VỀ VIỆC CÔNG BỐ DANH MỤC THUỐC BIỆT DƯỢC GỐC ĐỢT 1 - NĂ...QUYẾT ĐỊNH 371/QĐ-QLD VỀ VIỆC CÔNG BỐ DANH MỤC THUỐC BIỆT DƯỢC GỐC ĐỢT 1 - NĂ...
QUYẾT ĐỊNH 371/QĐ-QLD VỀ VIỆC CÔNG BỐ DANH MỤC THUỐC BIỆT DƯỢC GỐC ĐỢT 1 - NĂ...
 
QUYẾT ĐỊNH: 370/QĐ-QLD VỀ VIỆC BAN HÀNH DANH MỤC 50 THUỐC NƯỚC NGOÀI ĐƯỢC CẤP...
QUYẾT ĐỊNH: 370/QĐ-QLD VỀ VIỆC BAN HÀNH DANH MỤC 50 THUỐC NƯỚC NGOÀI ĐƯỢC CẤP...QUYẾT ĐỊNH: 370/QĐ-QLD VỀ VIỆC BAN HÀNH DANH MỤC 50 THUỐC NƯỚC NGOÀI ĐƯỢC CẤP...
QUYẾT ĐỊNH: 370/QĐ-QLD VỀ VIỆC BAN HÀNH DANH MỤC 50 THUỐC NƯỚC NGOÀI ĐƯỢC CẤP...
 
QUYẾT ĐỊNH VỀ VIỆC CÔNG BỐ DANH MỤC THUỐC CÓ CHỨNG MINH TƯƠNG ĐƯƠNG SINH HỌC ...
QUYẾT ĐỊNH VỀ VIỆC CÔNG BỐ DANH MỤC THUỐC CÓ CHỨNG MINH TƯƠNG ĐƯƠNG SINH HỌC ...QUYẾT ĐỊNH VỀ VIỆC CÔNG BỐ DANH MỤC THUỐC CÓ CHỨNG MINH TƯƠNG ĐƯƠNG SINH HỌC ...
QUYẾT ĐỊNH VỀ VIỆC CÔNG BỐ DANH MỤC THUỐC CÓ CHỨNG MINH TƯƠNG ĐƯƠNG SINH HỌC ...
 

Recently uploaded

ASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptxASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptx
AnushriSrivastav
 
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Levi Shapiro
 
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdfتقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
د حاتم البيطار
 
Benefits of Dentulu's Salivary Testing.pptx
Benefits of Dentulu's Salivary Testing.pptxBenefits of Dentulu's Salivary Testing.pptx
Benefits of Dentulu's Salivary Testing.pptx
Dentulu Inc
 
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptxASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
AnushriSrivastav
 

Recently uploaded (20)

Dr. Gaurav Gangwani: Leading Interventional Radiologist in Mumbai, India
Dr. Gaurav Gangwani: Leading Interventional Radiologist in Mumbai, IndiaDr. Gaurav Gangwani: Leading Interventional Radiologist in Mumbai, India
Dr. Gaurav Gangwani: Leading Interventional Radiologist in Mumbai, India
 
ASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptxASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF URINAL BY ANUSHRI SRIVASTAVA.pptx
 
Colonoscopy Screening And Age: Adapting Guidelines For Different Life Stages
Colonoscopy Screening And Age: Adapting Guidelines For Different Life StagesColonoscopy Screening And Age: Adapting Guidelines For Different Life Stages
Colonoscopy Screening And Age: Adapting Guidelines For Different Life Stages
 
CHAPTER- 1 NATIONAL-POLICIES-AND-LEGISLATION.pdf
CHAPTER- 1 NATIONAL-POLICIES-AND-LEGISLATION.pdfCHAPTER- 1 NATIONAL-POLICIES-AND-LEGISLATION.pdf
CHAPTER- 1 NATIONAL-POLICIES-AND-LEGISLATION.pdf
 
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...
 
2024 03 Monumental Mistakes in EMS BAD EMS v0.2.pdf
2024 03 Monumental Mistakes in EMS BAD EMS v0.2.pdf2024 03 Monumental Mistakes in EMS BAD EMS v0.2.pdf
2024 03 Monumental Mistakes in EMS BAD EMS v0.2.pdf
 
Ovarian Hyperstimulation Syndrome Case Presentation.pptx
Ovarian Hyperstimulation Syndrome Case Presentation.pptxOvarian Hyperstimulation Syndrome Case Presentation.pptx
Ovarian Hyperstimulation Syndrome Case Presentation.pptx
 
Jesse Jhaj: Building Relationships with Patients as a Doctor or Healthcare Wo...
Jesse Jhaj: Building Relationships with Patients as a Doctor or Healthcare Wo...Jesse Jhaj: Building Relationships with Patients as a Doctor or Healthcare Wo...
Jesse Jhaj: Building Relationships with Patients as a Doctor or Healthcare Wo...
 
Management of Colorectal Cancer for the Trainee Surgeon
Management of Colorectal Cancer for the Trainee SurgeonManagement of Colorectal Cancer for the Trainee Surgeon
Management of Colorectal Cancer for the Trainee Surgeon
 
The Best Foot and Ankle Center of Arizona
The Best Foot and Ankle Center of ArizonaThe Best Foot and Ankle Center of Arizona
The Best Foot and Ankle Center of Arizona
 
Pharmacology and Toxicology Thesis Defense by Slidesgo.pptx
Pharmacology and Toxicology Thesis Defense by Slidesgo.pptxPharmacology and Toxicology Thesis Defense by Slidesgo.pptx
Pharmacology and Toxicology Thesis Defense by Slidesgo.pptx
 
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdfتقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
 
Best Way 30-Days Keto Meal Plan For Diet
Best Way 30-Days Keto Meal Plan For DietBest Way 30-Days Keto Meal Plan For Diet
Best Way 30-Days Keto Meal Plan For Diet
 
Benefits of Dentulu's Salivary Testing.pptx
Benefits of Dentulu's Salivary Testing.pptxBenefits of Dentulu's Salivary Testing.pptx
Benefits of Dentulu's Salivary Testing.pptx
 
Valle Egypt Illustrates Consequences of Financial Elder Abuse
Valle Egypt Illustrates Consequences of Financial Elder AbuseValle Egypt Illustrates Consequences of Financial Elder Abuse
Valle Egypt Illustrates Consequences of Financial Elder Abuse
 
Digital Healthcare: The Future of Medical Consultations
Digital Healthcare: The Future of Medical ConsultationsDigital Healthcare: The Future of Medical Consultations
Digital Healthcare: The Future of Medical Consultations
 
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptxASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
ASSISTING WITH THE USE OF BED PAN BY ANUSHRI SRIVASTAVA.pptx
 
Sugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdf
Sugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdfSugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdf
Sugar Medicine_ Natural Homeopathy Remedies for Blood Sugar Management.pdf
 
Virtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdfVirtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdf
 
PhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptxPhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptx
 

Chứng nhận nhà sản xuất và phân phối nguyên liệu mỹ phẩm theo EFfCI

  • 1. Dr. Peter Ungeheuer Secretary General Mainzer Landstrasse 55 D - 60329 Frankfurt EFfCI Head Office: Avenue Louise 489, B-1050 Brussels  Phone: +49-69-25 5613 41 E-mail: Ungeheuer@effci.com Fax: +49-69-25 56 1342 HTTP://WWW.EFFCI.COM EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059 EFfCI GMP for Cosmetic Ingredients – Annex to 2017 Edition Cosmetic Ingredientmanufacturer anddistributor certification; Application of remote audits Frankfurt, January 14th , 2021 Purpose and Objectives: Conducting an EFfCI GMP audit may be impossible in the very exceptional situation where countries are in lockdown as a result of the COVID-19 pandemic crisis. The safety of people that conduct and receive audits is top priority for EFfCI and we support those governmental regulations which are aimed at reducing the impact of this virus. Even if travel was possible then company policies may mean many personnel are working from home and operational activities reduced or even halted. All these factors will have consequences with regards to EFfCI GMP Audits. The goal of this document is to describe alternative options where a physical audit is not permitted, to maintain or to renew the GMP Certification of Cosmetic Ingredient manufacturers and distributors. It indicates the conditions and time-periods which are acceptable to postpone a re-certification or surveillance audit or to replace it by a remote audit. It will be communicated to each EFfCI Registered Certification Body for implementation in their internal procedures. Supporting documents: - EFfCI GMP for Cosmetic Ingredients 2017 - EFfCI Position Paper: Cosmetic Ingredient manufacturer and distributor certification with regards to the COVID-19 outbreak (13 March 2020) - IAF ID3 2011 Guidance: International Accreditation Forum (IAF) Informative Document for Management of Extraordinary Events or Circumstances Affecting Accreditation Bodies, Certifying [Assessment] Bodies and Certified Organisations https://www.iaf.nu/articles/Informative_Documents_/32 1. Scope This document should be followed by EFfCI Registered Certification Bodies, when a scheduled audit is affected by an extraordinary circumstance such as a government- imposed travel ban, or other restrictions applied externally to the Cosmetic Ingredient manufacturer and/or supplier which are beyond their control. The annex applies to EFfCI GMP re-certification or surveillance audits and the first part of an initial Certification audit (Stage-1) audit. However, the full on-site initial Certification audit (Stage 2 audit) has to completed with a physical on-site audit. These requirements are valid while the COVID-19 pandemic containment measures are in place in the affected countries. It should remain valid until local or national travel restrictions are suspended, and physical (on-site) audits can return to normal.
  • 2. Dr. Peter Ungeheuer Secretary General Mainzer Landstrasse 55 D - 60329 Frankfurt EFfCI Head Office: Avenue Louise 489, B-1050 Brussels  Phone: +49-69-25 5613 41 E-mail: Ungeheuer@effci.com Fax: +49-69-25 56 1342 HTTP://WWW.EFFCI.COM EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059 2. Definitions Extraordinary event or circumstance: A circumstance beyond the control of the certified company, commonly referred to as “Force Majeure” or “act of God”. Examples are war, strike, riot, political instability, geopolitical tension, terrorism, crime, pandemic, flooding, earthquake, malicious computer hacking, other natural or man-made disasters. 3. Responsibilities It is the responsibility of the Certification Body to implement these requirements in its own system of procedures for communication to its team of auditors. The Certification Body shall also communicate these requirements to their impacted Cosmetic Ingredient Suppliers in case a certification audit cannot be performed for the above reason. It is the responsibility of the Certification Body to inform EFfCI aisbl (ungeheuer@effci.com) about the decision to either postpone or to perform a remote certification audit, before the audit is completed. 4. Procedure: conditions for postponement or remote audit 4.1. Initial Certification Audit When a new supplier of a Cosmetic Ingredient is willing to be certified with reference to the EFfCI GMP, the Stage 1 audit may be performed remotely. However, a Stage 2 audit cannot be conducted remotely. The Stage 2 certification audit shall be made no later than 6 months after the Stage 1 audit. If such conditions cannot be fulfilled, the best solution would be to wait until an on-site Stage 1 and Stage 2 certification audit can be completed. It is the decision of the Lead Auditor and of the Certification Body to accept a Stage 1 remote audit instead of on-site audit. Such a decision should consider the previous knowledge of the client, the scope of the certification, the size of the site, the number of products to be included in the assessment and the complexity of the production processes. The Lead Auditor should also take into consideration the probability for performing a Stage 2 on-site audit within a 6 months’ time period, before performing a remote Stage 1 audit. It is acknowledged that it may not be possible to perform a physical audit for Stage 2, and this may mean the application has to lapse. At this point EFfCI does not believe that this physical audit can be omitted without seriously compromising the reputation and value of the Certification Scheme to cosmetic manufacturers. 4.2. SurveillanceAudit a) When a Surveillance Audit 1 (SA-1) cannot be performed within one year after the Initial Certification Audit, or when a Surveillance Audit 2 (SA-2) cannot be performed within two years after the Initial Certification Audit, the physical audit can be delayed for a maximum of 6 months after the initial scheduled date. The initial scheduled date must be considered as the last day of the initial certification audit plus 12 or 24 months. Therefore, SA-1 should be conducted maximum 18 months after the initial certification audit and SA-2 should be conducted maximum 30 months after the initial certification audit date. The normal window which is applied to all scheduled audits should be respected based on the revised date.
  • 3. Dr. Peter Ungeheuer Secretary General Mainzer Landstrasse 55 D - 60329 Frankfurt EFfCI Head Office: Avenue Louise 489, B-1050 Brussels  Phone: +49-69-25 5613 41 E-mail: Ungeheuer@effci.com Fax: +49-69-25 56 1342 HTTP://WWW.EFFCI.COM EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059 b) If such an on-site audit is not possible for the reasons in the purpose and objectives, it may be acceptable to perform a remote audit in place of physical audit. This should be completed within the 6 month period after the initially scheduled audit date. The Certification Body shall as a first step perform a quality risk assessment considering the conditions mentioned in section 5.2 “Quality Risk Assessment for allowing a remote audit”. If the conclusion is that risk is low or moderate, the Certification Body can propose to the Supplier that a remote audit according to the procedure described in Section 5 can be conducted. The remote audit will then replace the on-site audit. If the SA-1 was already performed using remote means, then the SA-2 can also be a remote audit if the risk assessment is reviewed, revised and has a favorable conclusion (it is now permitted that there can be two successive remote surveillance audits). c) If the quality risk assessment concludes a remote audit is not acceptable, or if for any other reason a remote audit cannot be performed, then the EFfCI Certification shall be suspended for a maximum 6 months period and be withdrawn immediately after 6 months. d) In any case, the Certification Body should inform EFfCI aisbl at ungeheuer@effci.com about the audit’s postponement or the completion of a remote audit or a certification suspension, before the decision is implemented. 4.3. Re-certification Audit One of the following three options may be adopted: a) If a re-certification audit (RCA) cannot be performed within the normal window following the third anniversary of the Initial Certification Audit, the audit can be delayed for a maximum of 6 months after the third anniversary date. Therefore, an RCA should be conducted no later than 42 months after the initial certification audit date. In this case, there should be an extension of the expiry date of the certificate. b) If an on-site audit is not possible for the reasons in the purpose and objectives, it may be acceptable to perform a remote audit, in accordance with Section 5, in order to replace an on-site physical audit and to avoid certification suspension. That is the recertification audit in its entirety can be replaced by a remote audit. The Certification Body shall initially perform a quality risk assessment considering the conditions mentioned in Section 5.2 “Quality Risk Assessment for allowing a remote audit”. If the conclusion is that risk is low or moderate, the Certification Body can propose a remote audit according to the procedure described in Section 5. If the quality risk assessment is favorable, the remote audit shall be conducted within 6 months of the original planned RCA date, i.e., not more than 42 months after the initial certification audit (to allow time for planning and organizing the remote audit). In such an option, the remote audit shall also be confirmed by an on-site audit within the 6 month period after the date of the remote audit. In this case, there should be an extension of the expiry date of the certificate to the date of the remote audit. This means the physical audit will fall within the next audit cycle for the Certificate, but it should be an exceptional one off circumstance. This on-site audit duration can be shorter as the documentation was already assessed during the remote audit. c) If the quality risk assessment concludes a remote audit is not acceptable, or if no physical audit is possible within the 6 month extension in section a) then the EFfCI
  • 4. Dr. Peter Ungeheuer Secretary General Mainzer Landstrasse 55 D - 60329 Frankfurt EFfCI Head Office: Avenue Louise 489, B-1050 Brussels  Phone: +49-69-25 5613 41 E-mail: Ungeheuer@effci.com Fax: +49-69-25 56 1342 HTTP://WWW.EFFCI.COM EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059 Certification shall be suspended for a maximum 6 months period from the date of the original scheduled RCA and withdrawn immediately after.
  • 5. Dr. Peter Ungeheuer Secretary General Mainzer Landstrasse 55 D - 60329 Frankfurt EFfCI Head Office: Avenue Louise 489, B-1050 Brussels  Phone: +49-69-25 5613 41 E-mail: Ungeheuer@effci.com Fax: +49-69-25 56 1342 HTTP://WWW.EFFCI.COM EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059 d) In all cases, the Certification Body should inform EFfCI at ungeheuer@effci.com about the audit’s postponement, application of a remote audit or certification suspension, before the decision is implemented in order for this to be updated on the EFfCI website. 4.4. Certification Scope Changes Where an organization requires an additional location to be added to the scope of certification, then a physical audit of that location is required. If this cannot be completed then no change to the certification scope can be completed. 4.5. Certificate Validity The recertification date on Certificates will be retained as originally established. This means that if an audit is delayed under these rules and a new one issued the validity period of the new certificate will be the third year of the anniversary of the end of the validity of the previous certificate. That is, any delay to the audit will not increase the period of validity of the certificate. 5. Procedure: Organization ofa Remote audit A remote audit is an audit which is performed under a confidential disclosure agreement by remote tools (e.g.: phone, e-mails, Skype, WhatsApp, Zoom), with exchange of electronic documents using internet-cloud system when the size of document cannot be transferred by direct mails (e.g.: WeTransfer, Dropbox). The auditor may also be granted temporary access to the client’s IT systems to observe information directly. A remote audit is different from a questionnaire assessment as there should be a direct discussion between the auditor and the auditee, and the use of a video-conferencing system is essential. A remote audit is also different from a simple teleconference as the auditor shall have the opportunity to read and assess written audit evidence which is displayed on screen. At the end of the remote audit, it should be considered that, as far as audited topics are concerned, the Lead Auditor shall be able to provide a recommendation about the audit outcome with the same degree of confidence as after a physical audit. A remote audit does not have to include an on-site visit and audit of workshops, laboratories and warehouses but any visual evidence of these locations that can be provided is to be considered. 5.1. Confidentiality agreement The realisation of a remote audit will require some exchange of documents and photographs prior to the audit. Therefore, the existing confidentiality agreement may need to be revised and strengthened. The method of information exchange should be agreed in advance including the storage, processing, retaining and disposal of the shared information. There should be a prior commitment to keep confidential any information shared before and during the audit, and to not to copy or archive any photograph or document unless formally agreed by the auditee. 5.2. Quality Risk Assessment for allowing a remote audit A quality risk assessment should be performed by the Certification Body, with input from the client, before deciding if a remote audit can be conducted. EFfCI should be consulted if there is any doubt about the risk assessment outcome. The conclusion of the risk
  • 6. Dr. Peter Ungeheuer Secretary General Mainzer Landstrasse 55 D - 60329 Frankfurt EFfCI Head Office: Avenue Louise 489, B-1050 Brussels  Phone: +49-69-25 5613 41 E-mail: Ungeheuer@effci.com Fax: +49-69-25 56 1342 HTTP://WWW.EFFCI.COM EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059 assessment should be based on knowledge of the client, any publicly available information about their quality systems, and preliminary information provided by the client.
  • 7. Dr. Peter Ungeheuer Secretary General Mainzer Landstrasse 55 D - 60329 Frankfurt EFfCI Head Office: Avenue Louise 489, B-1050 Brussels  Phone: +49-69-25 5613 41 E-mail: Ungeheuer@effci.com Fax: +49-69-25 56 1342 HTTP://WWW.EFFCI.COM EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059 The risk assessment for determining whether to permit a remote audit, shall be documented. The risk assessment and the fact the audit was conducted remotely shall be clearly and prominently stated in the audit report. The risk assessment shall at a minimum consider the following items: - Changes to the certification scope (automatic high risk factor) - Changes to the production site address or major changes to the production facilities (e.g. new plant installed, new manufacturing process) (automatic high risk factor) - Changes to the types of Products manufactured in the same plant or using the same production equipment (automatic high risk factor) - Quality Complaint(s) communicated the Certification Body, concerning a Supplier Quality System deficiency (automatic high risk factor) - The number of major non-conformities at any or each of the previous two audits (more than three would be a high risk factor) - The history of closure of actions on the previous three audits - The numbers of all other observations (all types) in the previous three audits - Changes to the quality and or site management team since the last audit 5.3. Preparation and duration ofa remote audit The success of a remote audit will depend on the possibility for both the auditor and the auditee to have direct exchange concerning the quality matters that are not limited to a review of documentation only. The use of videoconference instead of a voice-only teleconference may facilitate such exchanges. It is also very important that auditor has a direct view of a requested document and the opportunity to ask questions and to receive immediate answers during the review. The time for connection with the attendees should be carefully managed, as well as the access to documents in the interviews. During the audit preparation phase the communication tools to be used shall be agreed. It is recommended these be tested, including the ability to exchange documents a few days before the audit. A list of documents which the auditor needs to see shall be communicated in advance, with the audit schedule. Additional documented evidence may be requested during the audit. In case translation is needed between the auditor and the auditee, the parties should agree prior to the audit how this will be managed. The total audit duration should be not less than the one defined for the original on-site physical audit. For instance, if a surveillance audit is defined to last one day, the remote surveillance audit should last not less than 8 hours. It is recommended to organise the remote audit agenda into several sections. This will allow named auditee’ employees to be present to discuss relevant concerns, and the auditor to have time to assess documents on their own. The remote audit may be organised over several days, with only a few hours per day for the interview. An example agenda corresponding to remote audit organisation is proposed in the Appendix. 5.4. Realisation of a remote audit The remote audit shall follow the same basic steps as a physical audit: - Audit program (the audit program should mention that it is a remote audit)
  • 8. Dr. Peter Ungeheuer Secretary General Mainzer Landstrasse 55 D - 60329 Frankfurt EFfCI Head Office: Avenue Louise 489, B-1050 Brussels  Phone: +49-69-25 5613 41 E-mail: Ungeheuer@effci.com Fax: +49-69-25 56 1342 HTTP://WWW.EFFCI.COM EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059 - Receipt of documents prior to the interview and study of them
  • 9. Dr. Peter Ungeheuer Secretary General Mainzer Landstrasse 55 D - 60329 Frankfurt EFfCI Head Office: Avenue Louise 489, B-1050 Brussels  Phone: +49-69-25 5613 41 E-mail: Ungeheuer@effci.com Fax: +49-69-25 56 1342 HTTP://WWW.EFFCI.COM EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059 - Opening meeting - Interview of Cosmetic Ingredient supplier teams - Assembly of objective evidence - Closing meeting - Audit Report issuance (The audit report should mention it is a remote audit which was justified based on a documented risk assessment.) - Supplier’s commitment for improvement – CAPA plan assessment - Final auditor recommendation regarding EFfCI GMP Certification status - Certification Body Certification decision - Communication of the certification conclusion If there is no remote visual visit to the plant (for example because of safety concerns such as explosive zoning), the auditor may request specific photographs of e.g., the production area and utilities. The auditor may also request raw data using a shared screen in case of electronic data or using webcam pictures of paper documentation. The organisation of such a remote audit should ensure when auditee representatives for each topic and each function are available in a timely manner. 5.5. Contentof the remote audit: Items to be audited The remote audit shall consider the key items listed in the EFfCI GMP Standard for Cosmetic Ingredients (non- exhaustive list): a) CAPA from the previous audit: Any previous preventive and corrective action plan should be reviewed, and evidence obtained (e.g. pictures and/or documents) to demonstrate action closure. This evidence may be requested during the audit preparation phase. b) List of Changes implemented since the previous audit: New equipment, new products, change of process, new activity within the site, change of organisation. For each change, an impact assessment should be available. Such change should be considered as of minor importance with regards to quality of manufactured Cosmetic Ingredient, otherwise a remote audit cannot replace an on-site audit. c) Annual Management Review: Performance of manufacturing operations and the quality system (e.g. Number of batches manufactured, number of batches rejected, customer complaints, recalls) Customer satisfaction assessment. Quality and GMP Objectives and Targets and the results of any previous ones d) Batch Record: At least one production and quality control batch record should be assessed by the auditor. The auditor should be able to select the batch record to be audited. A specific focus should be made on the testing, release and shipment process. e) Quality Control: Organisation of the QC, role and responsibilities. Audit of an actual analytical batch record with specific focus on raw data traceability Number of out-of-specification results recorded since previous audit. Issuance of Certificate of Analysis or Certificate of Conformity. f) Certification and Inspections
  • 10. Dr. Peter Ungeheuer Secretary General Mainzer Landstrasse 55 D - 60329 Frankfurt EFfCI Head Office: Avenue Louise 489, B-1050 Brussels  Phone: +49-69-25 5613 41 E-mail: Ungeheuer@effci.com Fax: +49-69-25 56 1342 HTTP://WWW.EFFCI.COM EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059 ISO 9001 audits and outcomes if those audits are performed separately to the EFfCI GMP audit.
  • 11. Dr. Peter Ungeheuer Secretary General Mainzer Landstrasse 55 D - 60329 Frankfurt EFfCI Head Office: Avenue Louise 489, B-1050 Brussels  Phone: +49-69-25 5613 41 E-mail: Ungeheuer@effci.com Fax: +49-69-25 56 1342 HTTP://WWW.EFFCI.COM EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059 g) Internal Audits Annual program, list and duration of the audits performed, process review Processes covered by the internal audit program since previous audit. h) Suppliers’ and Contractors’ Management New suppliers, monitoring of approved suppliers, audit of contractors, qualification evidence. i) Organisation roles and Responsibilities Number of employees (changes since previous audit), percentage of temporary employees. Organisation chart and corresponding job descriptions. j) Personnel Qualification GMP training program and realization Reference to EFfCI standards Example of training program traceability Management of consultants and temporary employees, if any k) Infrastructure and Working Environment Risk Assessments Changes to these documents resulting in new controls being applied to utilities, infrastructure and the working environment. 6. DocumentHistory 1 17th April 2020 First Issue 2 6th October 2020 Second edition with updates (in red text) 3 14th January 2021 Addition of Section 4.4 and 4.5 and editorial corrections
  • 12. Dr. Peter Ungeheuer Secretary General Mainzer Landstrasse 55 D - 60329 Frankfurt EFfCI Head Office: Avenue Louise 489, B-1050 Brussels  Phone: +49-69-25 5613 41 E-mail: Ungeheuer@effci.com Fax: +49-69-25 56 1342 HTTP://WWW.EFFCI.COM EFfCI is registered as AISBL, No 0840.955.059  EFfCI-VAT number: BE 0840.955.059 7. APPENDIX: Example ofRemote Audit Agenda Day Time Participant Topic to be audited Technical tool D-1 08:30 All Opening Meeting – roundtable, test of connection, scope – objectives Videoconference 09:15 concerned managers Discussion of CAPA from previous audit (based on document provided prior the audit) Videoconference 10:00 Break 10:15 Team 1 (e.g.: HR + QA) Topic 1 (e.g.: Training & personal qualification) webcam & shared screen 10:45 Team 2 Topic 2 webcam & shared screen 11:10 Team 3 Topic 3 webcam & shared screen 11:30 Auditee Team Leader Request for additional documentation e-Mail, Cloud transfer 11:45 Break 12:00 12:30 Auditee’s team Preliminary feedback after Day 1, documents to be prepared for Day 2 Videoconference D-1 Afternoon Auditor only Review documentation, request for additional evidence, communication to the auditee’s team leader Mail, phone, office work D-2 08:30 Auditee’s team Day-2 introduction meeting Program of the 2nd day Availability of Company representatives webcam & shared screen 09:00 Team 4 Topic 4 webcam & shared screen 09:20 Team 5 Topic 5 webcam & shared screen 09:40 Team 6 Topic 6 webcam & shared screen 10:00 Auditee’s team Auditor ask for documents, photographs, other evidence webcam & shared screen 10:05 Break 10:20 Ad-hoc team Last item(s) to be audited, last questions about provided documentation webcam & shared screen 11:15 Auditor time Room / Tool change 11:45 All Audit Conclusion meeting List of non-conformities and observations Videoconference 12:30 End of the audit